Seogsong Jeong1,2,3, Guijuan Luo2,3, Zhi-Heng Wang4, Meng Sha1, Lei Chen5,6, Qiang Xia7. 1. Department of Liver Surgery, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai, 200127, People's Republic of China. 2. International Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, 225 Changhai Road, Shanghai, 200438, People's Republic of China. 3. National Center for Liver Cancer, Shanghai, 201805, People's Republic of China. 4. The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, People's Republic of China. 5. International Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, 225 Changhai Road, Shanghai, 200438, People's Republic of China. chenlei@smmu.edu.cn. 6. Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China. chenlei@smmu.edu.cn. 7. Department of Liver Surgery, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai, 200127, People's Republic of China. xiaqiang@shsmu.edu.cn.
Abstract
BACKGROUND AND AIMS: To estimate the impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma. METHODS: We searched Pubmed and Embase for original articles that evaluated the impact of hepatitis B virus infection on outcomes of intrahepatic cholangiocarcinoma. The present study was conducted to generate odd ratios (ORs) with 95% confidence intervals (CIs) for pre-identified prognostic factors, overall survival, and recurrence. RESULTS: From 438 studies, we identified eight articles that compared outcomes between hepatitis B virus-infected patients and the others. In terms of clinicopathological characteristics, patients in the hepatitis B virus group significantly demonstrated single nodular tumor (OR 0.7; 95% CI 0.5-0.9; p = 0.01), infrequent lymph node metastasis (OR 0.5; 95% CI 0.3-0.6; p < 0.01), and infrequent perineural infiltration (OR 0.3; 95% CI 0.2-0.8; p < 0.01). No significant between-group differences were found in tumor diameter, vascular invasion, and tumor differentiation. Previous or temporary infection (seropositivity for hepatitis B core antibody) revealed no significant impact on clinicopathological characteristics. For survival outcomes, meta-analysis demonstrated that hepatitis B virus group had significantly better overall survival, recurrence rate, and median survival (p < 0.01). CONCLUSIONS: Our results suggest that hepatitis B virus infection is a powerful predictor of favorable survival outcomes for intrahepatic cholangiocarcinoma and significantly affects clinicopathological characteristics. Viral hepatitis B status needs to be taken into account and then establish therapeutic approaches.
BACKGROUND AND AIMS: To estimate the impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma. METHODS: We searched Pubmed and Embase for original articles that evaluated the impact of hepatitis B virus infection on outcomes of intrahepatic cholangiocarcinoma. The present study was conducted to generate odd ratios (ORs) with 95% confidence intervals (CIs) for pre-identified prognostic factors, overall survival, and recurrence. RESULTS: From 438 studies, we identified eight articles that compared outcomes between hepatitis B virus-infectedpatients and the others. In terms of clinicopathological characteristics, patients in the hepatitis B virus group significantly demonstrated single nodular tumor (OR 0.7; 95% CI 0.5-0.9; p = 0.01), infrequent lymph node metastasis (OR 0.5; 95% CI 0.3-0.6; p < 0.01), and infrequent perineural infiltration (OR 0.3; 95% CI 0.2-0.8; p < 0.01). No significant between-group differences were found in tumor diameter, vascular invasion, and tumor differentiation. Previous or temporary infection (seropositivity for hepatitis B core antibody) revealed no significant impact on clinicopathological characteristics. For survival outcomes, meta-analysis demonstrated that hepatitis B virus group had significantly better overall survival, recurrence rate, and median survival (p < 0.01). CONCLUSIONS: Our results suggest that hepatitis B virus infection is a powerful predictor of favorable survival outcomes for intrahepatic cholangiocarcinoma and significantly affects clinicopathological characteristics. Viral hepatitis B status needs to be taken into account and then establish therapeutic approaches.
Entities:
Keywords:
Cholangiocarcinoma; Clinicopathological characteristics; Hepatitis B virus; Liver cancer; Prognosis
Authors: Armin Thelen; Arne Scholz; Wilko Weichert; Bertram Wiedenmann; Peter Neuhaus; Reinhard Gessner; Christoph Benckert; Sven Jonas Journal: Am J Gastroenterol Date: 2009-12-08 Impact factor: 10.864